Hepatic Over-expression of Peroxisome Proliferator Activated Receptor Gamma2 in the Ob/ob Mouse Model of Non-insulin Dependent Diabetes Mellitus

Overview

Journal Mol Cell Biochem

Publisher Springer

Specialty Biochemistry

Date 2001 Nov 6

PMID 11693197

Citations 49

Authors

R Rahimian

E Masih-Khan

M Lo

C van Breemen

B M McManus

G P Dube

Affiliations

Soon will be listed here.

Abstract

Studies of the molecular basis of insulin resistance have focused on the peroxisome proliferator activated receptor gamma (PPARgamma, gamma1 and gamma2). The aim of this study was to determine whether the insulin resistance in liver of diabetic animals is associated with abnormal expression of these receptors. PPARgamma mRNA and protein expression levels were quantified in liver of 9-week-old male ob/ob mice as a model of diabetes and compared to age- and gender-matched wild type control animals of the same genetic background. Semi-quantitative reverse transcription-polymerase chain reaction, using 18S rRNA as an internal standard, indicated that PPARgamma2 mRNA was significantly upregulated in ob/ob liver vs. that in wild type mice. Western blotting revealed greater immunoreactivity of PPARgamma2 in liver from ob/ob mice relative to that in wild type mice. An index of insulin resistance (product of serum glucose and insulin concentration) was correlated with liver PPARgamma2 mRNA expression (r = 0.776; p < 0.001). The findings that liver PPARgamma2 expression is (1) significantly elevated in the ob/ob model of diabetes and (2) positively associated with an index of insulin resistance, suggests a possible compensatory response through which type II diabetic and obese organisms strive to maintain insulin sensitivity of the liver.

Citing Articles

Physiological and pathophysiological actions of insulin in the liver.

Kubota N, Kubota T, Kadowaki T Endocr J. 2024; 72(2):149-159.

PMID: 39231651 PMC: 11850106. DOI: 10.1507/endocrj.EJ24-0192.

Sex Differences in Hepatic Inflammation, Lipid Metabolism, and Mitochondrial Function Following Early Lipopolysaccharide Exposure in Epileptic WAG/Rij Rats.

Melini S, Trinchese G, Lama A, Cimmino F, Del Piano F, Comella F Antioxidants (Basel). 2024; 13(8).

PMID: 39199203 PMC: 11351225. DOI: 10.3390/antiox13080957.

The Role of Cannabidiol in Liver Disease: A Systemic Review.

Chen S, Kim J Int J Mol Sci. 2024; 25(4).

PMID: 38397045 PMC: 10888697. DOI: 10.3390/ijms25042370.

Hepatic Vagotomy in Patients With Obesity Leads to Improvement of the Cholesterol to High-Density Lipoprotein Ratio.

Catinis A, Hinojosa A, Leonardi C, Cook M Obes Surg. 2023; 33(12):3740-3745.

PMID: 37924466 DOI: 10.1007/s11695-023-06800-2.

First Evidence of Anti-Steatotic Action of Macrotympanain A1, an Amphibian Skin Peptide from .

Demori I, El Rashed Z, De Negri Atanasio G, Parodi A, Millo E, Salis A Molecules. 2022; 27(21).

PMID: 36364243 PMC: 9656375. DOI: 10.3390/molecules27217417.

References

Rieusset J, Andreelli F, Auboeuf D, Roques M, Vallier P, Riou J . Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes. Diabetes. 1999; 48(4):699-705. DOI: 10.2337/diabetes.48.4.699. View

Duncan M, Singh B, Wise P, Carter G, Alaghband-Zadeh J . A simple measure of insulin resistance. Lancet. 1995; 346(8967):120-1. DOI: 10.1016/s0140-6736(95)92143-5. View

Mukherjee R, Davies P, Crombie D, Bischoff E, Cesario R, Jow L . Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature. 1997; 386(6623):407-10. DOI: 10.1038/386407a0. View

Park K, Ciaraldi T, Lindgren K, Mudaliar S, Nikoulina S, Tufari S . Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-gamma. J Clin Endocrinol Metab. 1998; 83(8):2830-5. DOI: 10.1210/jcem.83.8.5034. View

Weinstein S, Holand A, OBoyle E, Haber R . Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle. Metabolism. 1993; 42(10):1365-9. DOI: 10.1016/0026-0495(93)90139-f. View

Barroso I, Gurnell M, Crowley V, Agostini M, Schwabe J, Soos M . Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 2000; 402(6764):880-3. DOI: 10.1038/47254. View

Issemann I, Green S . Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990; 347(6294):645-50. DOI: 10.1038/347645a0. View

Tontonoz P, Hu E, Spiegelman B . Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994; 79(7):1147-56. DOI: 10.1016/0092-8674(94)90006-x. View

Houseknecht K, Portocarrero C . Leptin and its receptors: regulators of whole-body energy homeostasis. Domest Anim Endocrinol. 1998; 15(6):457-75. DOI: 10.1016/s0739-7240(98)00035-6. View

10.

Edvardsson U, Bergstrom M, Alexandersson M, Bamberg K, LJUNG B, Dahllof B . Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res. 1999; 40(7):1177-84. View

11.

Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K . Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest. 1998; 101(6):1354-61. PMC: 508690. DOI: 10.1172/JCI1235. View

12.

Su J, Simmons C, Wisely B, Ellis B, Winegar D . Monitoring of PPAR alpha protein expression in human tissue by the use of PPAR alpha-specific MAbs. Hybridoma. 1998; 17(1):47-53. DOI: 10.1089/hyb.1998.17.47. View

13.

Vidal-Puig A, Jimenez-Linan M, Lowell B, Hamann A, Hu E, Spiegelman B . Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest. 1996; 97(11):2553-61. PMC: 507341. DOI: 10.1172/JCI118703. View

14.

Berger J, Bailey P, Biswas C, Cullinan C, Doebber T, Hayes N . Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996; 137(10):4189-95. DOI: 10.1210/endo.137.10.8828476. View

15.

Hallakou S, Doare L, Foufelle F, Kergoat M, Guerre-Millo M, Berthault M . Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes. 1997; 46(9):1393-9. DOI: 10.2337/diab.46.9.1393. View

16.

Kliewer S, Lenhard J, Willson T, Patel I, Morris D, Lehmann J . A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell. 1995; 83(5):813-9. DOI: 10.1016/0092-8674(95)90194-9. View

17.

Thuillier P, Baillie R, Sha X, Clarke S . Cytosolic and nuclear distribution of PPARgamma2 in differentiating 3T3-L1 preadipocytes. J Lipid Res. 1998; 39(12):2329-38. View

18.

Tominaga M, Igarashi M, Daimon M, Eguchi H, Matsumoto M, Sekikawa A . Thiazolidinediones (AD-4833 and CS-045) improve hepatic insulin resistance in streptozotocin-induced diabetic rats. Endocr J. 1993; 40(3):343-9. DOI: 10.1507/endocrj.40.343. View

19.

Groop L . Pathogenesis of insulin resistance in type 2 diabetes: a collision between thrifty genes and an affluent environment. Drugs. 1999; 58 Suppl 1:11-2; discussion 75-82. DOI: 10.2165/00003495-199958001-00004. View

20.

Vidal-Puig A, Considine R, Jimenez-Linan M, Werman A, Pories W, Caro J . Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest. 1997; 99(10):2416-22. PMC: 508081. DOI: 10.1172/JCI119424. View